DexCom (NASDAQ:DXCM) shares surged Friday on the back of its strong third-quarter earnings performance and full-year revenue guidance increase, which was reported after the close Thursday.
The company, which creates glucose monitoring systems for diabetes management, reported EPS of $0.50, $0.16 better than the analyst estimate of $0.34, while revenue for the quarter came in at $975 million, up 27% YoY and higher than the consensus estimate of $939.19 million.
DexCom shares have rallied more than 15%, trading above the $94 per share mark.
Its U.S. revenue grew by 24% during the quarter, while international revenue increased by 33%. The company said it "executed incredibly well," and its continued momentum left it in a great position to again raise its full-year revenue and margin guidance.
The company now sees FY2023 revenue between $3.575B and $3.6B, up from the previous range of $ 3.5B to $3.55B. The consensus estimate was $3.539B.